Pipeline栓塞装置(PED)Shield与PED/PED Flex血栓栓塞事件比较:倾向性评分匹配分析
单中心回顾性分析2013至2023年543例患者707个动脉瘤,比较PED Shield与PED一代/PED Flex的血栓栓塞事件。倾向性评分匹配84对后,PED Shield血栓栓塞事件率3.57% vs PED一代/PED Flex 10.71%(P=0.07),再治疗率2.38% vs 8.32%(P=0.09),均未达统计学显著。
要点
- PED Shield组血栓栓塞事件率3.57%,PED一代/PED Flex组10.71%,差异未达统计学显著(P=0.07)。
- PED Shield组再治疗率2.38%,PED Flex组8.32%,差异未达统计学显著(P=0.09)。
- 两组首次及末次影像随访完全闭塞率、支架内狭窄、出血并发症及功能结局均相当。
核心结论
- 本研究是文献中首个采用倾向性评分匹配比较PED与PED Shield的研究,提示PED Shield血栓栓塞事件有降低趋势,即使控制了阿司匹林和氯吡格雷抵抗后亦然,再治疗率也有降低趋势,但均未达统计学显著。
研究设计与样本
- 单中心学术机构回顾性分析,纳入2013至2023年接受PED一代/PED Flex或PED Shield治疗的动脉瘤。
- 共543例患者707个动脉瘤,经605次手术完成治疗;PED Shield治疗156个动脉瘤(22.07%),无Shield技术551个(77.93%)。
- 倾向性评分匹配控制年龄、吸烟史、糖尿病、既往蛛网膜下腔出血、治疗前改良Rankin量表评分、动脉瘤位置、动脉瘤大小、既往治疗及氯吡格雷或阿司匹林抵抗等混杂因素,匹配后得到84对。
- 分析围手术期及术后血栓栓塞事件,使用Stata 14进行数据分析。
主要发现
- PED Shield组血栓栓塞事件率为3.57%,PED一代/PED Flex组为10.71%(P=0.07)。
- PED Shield组再治疗率为2.38%,PED Flex组为8.32%(P=0.09)。
- 两组首次影像随访完全闭塞(P=0.41)和末次影像随访完全闭塞(P=0.71)相当。
- 两组支架内狭窄(P=0.95)、出血并发症(P=0.31)及功能结局(P=0.66)均相当。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: The pipeline embolization device (PED) Flex with Shield technology is a third-generation flow diverter used for intracranial aneurysm treatment designed to decrease thrombogenicity through a phosphorylcholine coating. Herein, we aim to compare the rate of thromboembolic events in PED with Shield technology and PED without it through propensity score matching. METHODS: We conducted a retrospective analysis of aneurysms treated with PED first-generation/PED Flex and PED with Shield between 2013 and 2023 at a single academic institution. Patients were matched through propensity score by controlling for confounding factors including age, smoking history, diabetes, previous subarachnoid hemorrhage, modified Rankin Scale pretreatment, location, aneurysm size, previous treatment, and clopidogrel or aspirin resistance. After matching, we evaluated for periprocedural and postoperative thromboembolic events. Data analysis was performed using Stata 14. RESULTS: A total of 543 patients with 707 aneurysms treated in 605 procedures were included in the analysis. From these, 156 aneurysms were treated with PED with Shield (22.07%) and 551 (77.93%) without Shield technology. Propensity score matching resulted in 84 matched pairs. The rate of thromboembolic events was 3.57% for PED Shield and 10.71% for PED first-generation/PED Flex ( P = .07), while retreatment rates were 2.38% for PED Shield and 8.32% for PED Flex ( P = .09). Complete occlusion at first ( P = .41) and last imaging follow-up ( P = .71), in-stent stenosis ( P = .95), hemorrhagic complications ( P = .31), and functional outcomes ( P = .66) were comparable for both groups. CONCLUSION: This is the first study in the literature performing a propensity scored-matched analysis comparing PED with PED with Shield technology. Our study suggests a trend toward lower thromboembolic events for PED Shield, even after controlling for aspirin and clopidogrel resistance, and a trend toward lower aneurysm retreatment rates with PED Shield, without reaching statistical significance.
引用
- Ramirez-Velandia F, Enriquez-Marulanda A, Filo J, et al. Comparison of Thromboembolic Events Between Pipeline Embolization Device (PED) Shield and PED/PED Flex: A Propensity Score-Matched Analysis. Neurosurgery. 2024. PMID: 38391195. doi:10.1227/neu.0000000000002883
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。